睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 16 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 16

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京医院Beijing Hospital北京医院页面
  2. 研究中心中国人民解放军总医院Chinese PLA General Hospital北京医院页面
  3. 研究中心中山大学附属第五医院Fifth Affiliated Hospital of Sun Yat-sen University珠海医院页面
  4. 研究中心蚌埠医学院第一附属医院First Affiliated Hospital of Bengbu Medical University蚌埠医院页面
  5. 研究中心大连医科大学附属第一医院First Affiliated Hospital of Dalian Medical University大连医院页面
  6. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  7. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  8. 研究中心福建医科大学附属协和医院Fujian Medical University Union Hospital福州医院页面
  9. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  10. 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
  11. 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
  12. 研究中心中国医科大学附属盛京医院Shengjing Hospital of China Medical University沈阳医院页面
  13. 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
  14. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  15. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面
  16. 研究中心南方医科大学珠江医院Zhujiang Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05024214,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. phase Ib:Histological or cytological diagnosis of Locally advanced or metastatic solid tumors (excluding hepatocellular carcinoma and thyroid carcinoma) that have progressed after standard treatment or are intolerant or have no effective treatment;

    入选标准第 2 条

    phase II cohort 1:Histological or cytological diagnosis of NSCLC,RCC, HCC, resistance to previous treatment with PD-(L)1 inhibitor; previous system treatment lines≤2;

    入选标准第 3 条

  3. Prior anticancer treatment within 4 weeks prior to the first dose of study drugs;

    排除标准第 1 条

    Toxicity from prior anticancer therapy prior to the first dose of study drugs not recovered to ≤ grade1;

    排除标准第 2 条

    Have used or require treatment with >10 mg/day of prednisone or an equivalent dose of systemic corticosteroids within 14 days prior to the first dose of study drugs;

    排除标准第 8 条

  4. phase Ib and phase II cohort 1: Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1; Phase II cohort 2: Karnofsky physical status (KPS) assessment ≥70;

    入选标准第 6 条

  5. At least one measurable lesion per RECIST 1.1;

    入选标准第 8 条

  6. Have other primary malignancies within 5 years;

    排除标准第 16 条

  7. Women who are pregnant or breastfeeding.

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05024214,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Eighteen years and older;
  2. phase Ib:Histological or cytological diagnosis of Locally advanced or metastatic solid tumors (excluding hepatocellular carcinoma and thyroid carcinoma) that have progressed after standard treatment or are intolerant or have no effective treatment;
  3. phase II cohort 1:Histological or cytological diagnosis of NSCLC,RCC, HCC, resistance to previous treatment with PD-(L)1 inhibitor; previous system treatment lines≤2;
  4. phase II cohort 2:Unresectable locally advanced or metastatic or recurrent RCC;
  5. Tumor tissue samples or biopsies from FFPE archived or fresh biopsies with locally advanced/metastatic disease must be provided, and if biopsies are not available, samples obtained prior to receiving adjuvant/neoadjuvant chemotherapy are allowed;
  6. phase Ib and phase II cohort 1: Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1; Phase II cohort 2: Karnofsky physical status (KPS) assessment ≥70;
  7. Life expectancy of at least 12 weeks;
  8. At least one measurable lesion per RECIST 1.1;
  9. Adequate organ function;
  10. Signed informed consent.

排除标准:Exclusion Criteria:

  1. Prior anticancer treatment within 4 weeks prior to the first dose of study drugs;
  2. Toxicity from prior anticancer therapy prior to the first dose of study drugs not recovered to ≤ grade1;
  3. Hypertension did not satisfactory controlled after antihypertensive medication
  4. Phase Ib/II: Subjects who were previously treated with Lenvatinib or who participated in a clinical trial of a generic version of Lenvatinib
  5. Phase II cohort 1, intolerance to treatment with A PD-(L)1 inhibitor; History of severe digestive disease that can affect the oral absorption of Lenvatinib/Sunitinib;
  6. Uncontrollable or significant cardiovascular or cerebrovascular disease;
  7. Active, known history or suspected autoimmune disease;
  8. Have used or require treatment with >10 mg/day of prednisone or an equivalent dose of systemic corticosteroids within 14 days prior to the first dose of study drugs;
  9. have received live attenuated vaccine within 28 days prior to the first study drug treatment or are scheduled to receive it during the study period;
  10. Subjects with known or suspected interstitial pneumonia;
  11. Any serious active infection requiring systemic antibacterial, antifungal or antiviral therapy at screening, including active tuberculosis; Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
  12. Active hepatitis B or hepatitis C;
  13. Known history of severe gastrointestinal bleeding or active hemoptysis or other severe bleeding within 6 months prior to first study drug therapy;
  14. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage ;
  15. Known active or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis;
  16. Have other primary malignancies within 5 years;
  17. Known history of contraindications or hypersensitivity reactions to any investigational drug component or any known excipients
  18. Women who are pregnant or breastfeeding.
  19. Radiographic evidence of major blood vessel invasion/infiltration may be considered for enrollment if the investigator assesses that the risk is manageable.

引自 ClinicalTrials.gov, NCT05024214, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05024214,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05024214